Displaying drugs 14751 - 14775 of 15269 in total
N-oxo-2-(phenylsulfonylamino)ethanamide
Experimental
N-(3-AMINOPROPYL)-2-NITROBENZENAMINE
Experimental
123I-iodometomidate
123I-iodometomidate is under investigation in clinical trial NCT00454103 (Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy).
Investigational
NB-124 sulfate
Investigational
Matched Iupac: … -dihydroxyoxolan-2-yl]oxy}-3-hydroxycyclohexyl]oxy}-2-[(1R)-1-hydroxyethyl]oxane-3,4-diol; sulfuric acid …
Altropane I-123
Altropane I-123 is under investigation in clinical trial NCT01950468 (A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes).
Investigational
Matched Description: … in clinical trial NCT01950468 (A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and …
4-(2-amino-1,3-thiazol-4-yl)phenol
Experimental
1-(2-HYDROXYETHYLOXYMETHYL)-6-PHENYL THIOTHYMINE
Experimental
iCo-007
iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis) such as age-related macular degeneration (AMD) and diabetic retinopathy(DR).
Investigational
Matched Description: … by the formation of new blood vessels (angiogenesis) such as age-related macular degeneration (AMD) and …
JPC-3210
JPC-3210 is a potent antimalarial agent. It is an erythrocytic schizonticide with potent in vitro antimalarial activity against multidrug-resistant Plasmodium falciparum lines, low cytotoxicity, potent in vivo efficacy against murine malaria, and favourable preclinical pharmacokinetics including a lengthy plasma elimination half-life.
Experimental
Matched Description: … multidrug-resistant _Plasmodium falciparum_ lines, low cytotoxicity, potent in vivo efficacy against murine malaria, and …
Prolectin-M
Prolectin-M is a (1-6)-alpha-D-mannopyranose and acts as an antagonist of galectin. It is being investigated in the clinical trial NCT04512027 (Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support. (Prolectin-M)).
Investigational
Matched Description: … Prolectin-M is a (1-6)-alpha-D-mannopyranose[L31338] and acts as an antagonist of galectin. …
Elsubrutinib
Elsubrutinib is under investigation in clinical trial NCT04451772 (A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State).
Investigational
Matched Description: … under investigation in clinical trial NCT04451772 (A Study of the Safety of Oral Elsubrutinib Capsules and …
Displaying drugs 14751 - 14775 of 15269 in total